Sonic Healthcare Ltd SKHCF
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Sonic Healthcare is a global pathology provider holding the largest market share positions in Australia, Germany, Switzerland and the U.K., the number two position in Belgium and New Zealand and is the third largest provider in the U.S. In addition to pathology laboratories which contribute 85% of revenue, Sonic is a major player in diagnostic imaging and the provision of primary care medical centres in Australia. The company earns 36% of revenue in Australia and New Zealand, 27% in the U.S. and the balance in Europe. Organic growth of the Laboratories segment typically runs between 3% and 5% per year and the company regularly makes acquisitions to enhance its growth.
Sydney, NSW, 2000, Australia